NASDAQ:AKRO Akero Therapeutics - AKRO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $37.45 -2.39 (-6.00%) (As of 03/24/2023 08:50 PM ET) Add Compare Share Share Today's Range$37.40▼$39.8250-Day Range$37.27▼$50.2452-Week Range$7.52▼$54.88Volume1.07 million shsAverage Volume596,904 shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$52.40 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Akero Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside39.9% Upside$52.40 Price TargetShort InterestHealthy7.26% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.71Based on 14 Articles This WeekInsider TradingSelling Shares$5.16 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.95) to ($3.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector217th out of 995 stocksPharmaceutical Preparations Industry88th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.40, Akero Therapeutics has a forecasted upside of 39.9% from its current price of $37.45.Amount of Analyst CoverageAkero Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.26% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Akero Therapeutics has recently decreased by 5.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 2.6 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Akero Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,161,061.00 in company stock.Percentage Held by Insiders10.38% of the stock of Akero Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.76% of the stock of Akero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($2.95) to ($3.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -12.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 7.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akero Therapeutics (NASDAQ:AKRO) StockAkero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.Read More Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Sees Unusually-High Trading Volume Following Analyst UpgradeMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Akero Therapeutics (AKRO)March 27, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 23, 2023 | americanbankingnews.comCanaccord Genuity Group Increases Akero Therapeutics (NASDAQ:AKRO) Price Target to $58.00March 22, 2023 | finance.yahoo.comTop 1% Biotech 89bio Scores 29% Gain As Battle In Liver Disease Heats UpMarch 22, 2023 | finance.yahoo.com89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver DiseaseMarch 22, 2023 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Trading Down 4.3%March 22, 2023 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) to Post Q1 2023 Earnings of ($0.71) Per Share, HC Wainwright ForecastsMarch 27, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 21, 2023 | benzinga.comAkero Therapeutics Stock (NASDAQ:AKRO), Guidance and ForecastMarch 20, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Akero Therapeutics (AKRO)March 17, 2023 | finance.yahoo.comAkero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 14, 2023 | seekingalpha.comAKRO Akero Therapeutics, Inc.March 10, 2023 | theglobeandmail.comMarkets Today: Stocks Rally as Concern Eases About Aggressive FedFebruary 11, 2023 | reuters.comAKRO.OJanuary 27, 2023 | 247wallst.comFirst Look Analysts Research Calls for Friday, January 27January 10, 2023 | finance.yahoo.comAkero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial StrategyJanuary 4, 2023 | finance.yahoo.comAkero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 22, 2022 | finance.yahoo.comAkero Therapeutics Outlines Expected 2023 Milestones For Lead NASH ProgramDecember 21, 2022 | finance.yahoo.comAkero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 MilestonesDecember 20, 2022 | finance.yahoo.comMadrigal (MDGL) Soars as Resmetirom Meets Goal in NASH StudyDecember 8, 2022 | finance.yahoo.comEfruxifermin Granted FDA Breakthrough Therapy Designation for NASHNovember 17, 2022 | nasdaq.comNoteworthy Thursday Option Activity: ETSY, AKRO, MANNovember 13, 2022 | finance.yahoo.comAkero Therapeutics, Inc.'s (NASDAQ:AKRO) large institutional owners must be happy as stock continues to impress, up 5.6% over the past weekNovember 10, 2022 | finance.yahoo.comAkero Therapeutics to Present at Upcoming Healthcare Conferences in NovemberNovember 8, 2022 | finance.yahoo.comAre Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?November 7, 2022 | benzinga.comAkero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD's The Liver Meeting® 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Company Calendar Last Earnings11/12/2021Today3/26/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.40 High Stock Price Forecast$65.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+39.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.44% Return on Assets-41.06% Debt Debt-to-Equity Ratio0.03 Current Ratio18.61 Quick Ratio14.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book7.72Miscellaneous Outstanding Shares46,970,000Free Float42,095,000Market Cap$1.76 billion OptionableNot Optionable Beta-0.91 Key ExecutivesAndrew ChengPresident, Chief Executive Officer & DirectorJonathan YoungChief Operating Officer & Executive Vice PresidentWilliam R. WhiteCFO, Treasurer, EVP & Head-Corporate DevelopmentTimothy RolphChief Scientific OfficerReshma ShringarpureVice President-Clinical Research & Medical AffairsKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHFibroGenNASDAQ:FGENPacira BioSciencesNASDAQ:PCRXCatalyst PharmaceuticalsNASDAQ:CPRXSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 2,699 shares on 3/23/2023Ownership: 0.039%Andrew ChengSold 25,000 sharesTotal: $1.17 M ($46.65/share)Voya Investment Management LLCBought 25,818 shares on 2/28/2023Ownership: 0.079%Parallax Volatility Advisers L.P.Sold 50,000 shares on 2/27/2023Ownership: 0.000%Alliancebernstein L.P.Bought 10,052 shares on 2/16/2023Ownership: 0.074%View All Insider TransactionsView All Institutional Transactions AKRO Stock - Frequently Asked Questions Should I buy or sell Akero Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks. What is Akero Therapeutics' stock price forecast for 2023? 4 brokerages have issued 1 year price targets for Akero Therapeutics' shares. Their AKRO share price forecasts range from $25.00 to $65.00. On average, they expect the company's stock price to reach $52.40 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts. How have AKRO shares performed in 2023? Akero Therapeutics' stock was trading at $54.80 at the start of the year. Since then, AKRO stock has decreased by 31.7% and is now trading at $37.45. View the best growth stocks for 2023 here. When is Akero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our AKRO earnings forecast. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.70) EPS for the quarter, topping analysts' consensus estimates of ($0.91) by $0.21. What ETFs hold Akero Therapeutics' stock? ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Invesco DWA SmallCap Momentum ETF (DWAS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC). What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS). When did Akero Therapeutics IPO? (AKRO) raised $75 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI acted as the underwriters for the IPO and Roth Capital Partners was co-manager. What is Akero Therapeutics' stock symbol? Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO." Who are Akero Therapeutics' major shareholders? Akero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Avidity Partners Management LP (8.18%), Skorpios Trust (7.00%), Alkeon Capital Management LLC (6.94%), Price T Rowe Associates Inc. MD (5.13%), Marshall Wace LLP (3.22%) and Geode Capital Management LLC (1.35%). Insiders that own company stock include Andrew Cheng, Apple Tree Partners Iv, LP, Catriona Yale, Global Strategic Fund I Venbio, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph and William Richard White. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akero Therapeutics' stock price today? One share of AKRO stock can currently be purchased for approximately $37.45. How much money does Akero Therapeutics make? Akero Therapeutics (NASDAQ:AKRO) has a market capitalization of $1.76 billion. The company earns $-112,030,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. How can I contact Akero Therapeutics? Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.akerotx.com. The company can be reached via phone at (650) 487-6488 or via email at akero@sternir.com. This page (NASDAQ:AKRO) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.